Page 2 - Adv Hematol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

22 febbraio 2021 17:11 Fonte: Adnkronos #chimica-e-farmacia - LACHEN, Switzerland, Feb. 22, 2021 /PRNewswire/ -- Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. "Simoctocog Alfa (Nuwiq®) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study" https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623).  The...

Octapharma AG: Final data from the NuProtect study published on the immunogenicity of Nuwiq in previously untreated patients with severe haemophilia A in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. "Simoctocog Alfa (Nuwiq ) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study" https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623). The NuProtect study (NCT01712438; EudraCT 2012-002554-23) was a prospective...

Octapharma Final Data From the NuProtect Study Published on the Immunogenicity of Nuwiq® in Previously Untreated Patients With Severe Haemophilia A Thursday, February 18, 2021 4:01PM IST (10:31AM GMT)   LACHEN, Switzerland:   Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq ® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. “Simoctocog Alfa (Nuwiq ®) in Prev...

Octapharma: Final Data From the NuProtect Study Published on the Immunogenicity of Nuwiq in Previously Untreated Patients With Severe Haemophilia A in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. "Simoctocog Alfa (Nuwiq ) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study" https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623). The NuProtect study (NCT01712438; EudraCT 2012-002554-23) was a prospective, m...

Share: Octapharma announced today a satellite symposium and poster presentation at the 14th annual congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which will be held virtually from February 3–5, 2021. The satellite symposium, A family journey with Nuwiq ®: Early treatment decisions for long-term health, will be chaired by Dr Robert F. Sidonio Jr. (Hemophilia of Georgia Center for Bleeding and Clotting Disorders, Children's Healthcare of Atlanta, Emory University, Atlanta, USA) and will follow the treatment journey of a family with two sons diagnosed with...